A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

BACKGROUND: The cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors. DESIGN: FOLFIRI + flavopiridol were administered every 2 weeks. Based on sequence-de...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Dickson, Mark A., Shah, Manish A., Rathkopf, Dana, Tse, Archie, Carvajal, Richard D., Wu, Nian, Lefkowitz, Robert A., Gonen, Mithat, Cane, Lauren M., Dials, Heather J., Schwartz, Gary K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2957673/
https://ncbi.nlm.nih.gov/pubmed/20953860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1269-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia